BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 21129746)

  • 1. Do lipids and apolipoproteins predict coronary heart disease under statin and fibrate therapy in the primary prevention setting in community-dwelling elderly subjects? The 3C Study.
    Straczek C; Tafflet M; Barberger-Gateau P; Bertrand M; Dupuy AM; Ducimetière P; Empana JP
    Atherosclerosis; 2011 Feb; 214(2):426-31. PubMed ID: 21129746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism.
    Delluc A; Malécot JM; Kerspern H; Nowak E; Carre JL; Mottier D; Le Gal G; Lacut K
    Atherosclerosis; 2012 Jan; 220(1):184-8. PubMed ID: 22035572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study.
    Canouï-Poitrine F; Luc G; Bard JM; Ferrieres J; Yarnell J; Arveiler D; Morange P; Kee F; Evans A; Amouyel P; Ducimetiere P; Empana JP;
    Cerebrovasc Dis; 2010 Aug; 30(3):252-9. PubMed ID: 20664258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women.
    Everett BM; Kurth T; Buring JE; Ridker PM
    J Am Coll Cardiol; 2006 Dec; 48(11):2235-42. PubMed ID: 17161253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher level of systemic C-reactive protein is independently predictive of coronary heart disease in older community-dwelling adults: the three-city study.
    Straczek C; Ducimetiere P; Barberger-Gateau P; Helmer C; Ritchie K; Jouven X; Carcaillon L; Amouyel P; Tzourio C; Empana JP
    J Am Geriatr Soc; 2010 Jan; 58(1):129-35. PubMed ID: 20002508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
    Gotto AM
    Atheroscler Suppl; 2007 Aug; 8(2):3-8. PubMed ID: 17588826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
    Ingelsson E; Schaefer EJ; Contois JH; McNamara JR; Sullivan L; Keyes MJ; Pencina MJ; Schoonmaker C; Wilson PW; D'Agostino RB; Vasan RS
    JAMA; 2007 Aug; 298(7):776-85. PubMed ID: 17699011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
    Al-Waili K; Al-Zakwani I; Al-Dughaishi T; Baneerje Y; Al-Sabti H; Al-Hashmi K; Farhan H; Habsi KA; Al-Hinai AT; Al-Rasadi K
    Angiology; 2014 May; 65(5):430-5. PubMed ID: 23564019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines.
    Shai I; Rimm EB; Hankinson SE; Curhan G; Manson JE; Rifai N; Stampfer MJ; Ma J
    Circulation; 2004 Nov; 110(18):2824-30. PubMed ID: 15492318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics.
    Vincenzi B; Borba CP; Gray DA; Copeland PM; Wang X; Fan X; Aragam GG; Henderson DC
    Ann Clin Psychiatry; 2013 May; 25(2):141-8. PubMed ID: 23638445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lipid measures and incident coronary heart disease: Tehran Lipid & Glucose Study.
    Nejat A; Mirbolouk M; Mohebi R; Hasheminia M; Tohidi M; Saadat N; Azizi F; Hadaegh F
    Clin Biochem; 2014 Sep; 47(13-14):1239-44. PubMed ID: 24657509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
    Kastelein JJ; van der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA; Szarek M; LaRosa JC; Pedersen TR; Grundy SM; ;
    Circulation; 2008 Jun; 117(23):3002-9. PubMed ID: 18519851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.